Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 6/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504228 | 0.85 | AR (0.34) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL5506839 | 0.75 | HSD17B10 (0.39) | KDM4EMEN1KMT2APIK3CGLMNA | |
| SCHEMBL5501787 | 0.74 | AR (0.32) | KDM4EAR | |
| SCHEMBL5505190 | 0.72 | KDM4E (0.35) | CYP1A2KDM4EMAPK1 | |
| SCHEMBL5504872 | 0.71 | — | — | |
| SCHEMBL5500674 | 0.65 | KDM4E (0.34) | KDM4EMAPK1 | |
| SCHEMBL5500552 | 0.65 | KDM4E (0.34) | KDM4EMAPK1 | |
| SCHEMBL5500602 | 0.65 | TSHR (0.39) | PIK3CGPIM1TSHR | |
| SCHEMBL10568147 | 0.64 | PTGS1 (0.44) | CYP1A2KDM4EMEN1KMT2ALMNA | |
| SCHEMBL5505826 | 0.64 | KDM4E (0.33) | KDM4EAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846108-A2 | KERATIN DYEING COMPOSITIONS CONTAINING BENZOTHIAZOLE-4,7-DIAMINES, AND USE THEREOF | The Procter & Gamble Company (US) | 2007-10-24 | — | — | EP | claimed |
| WO-2006078800-A2 | KERATIN DYEING COMPOSITIONS CONTAINING BENZOTHIAZOLE-4-, 7-DIAMINES, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-27 | — | — | WO | claimed |
| US-20060162099-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2006-07-27 | — | — | US | claimed |
| EP-1846108-A2 | KERATIN DYEING COMPOSITIONS CONTAINING BENZOTHIAZOLE-4,7-DIAMINES, AND USE THEREOF | The Procter & Gamble Company (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006078800-A2 | KERATIN DYEING COMPOSITIONS CONTAINING BENZOTHIAZOLE-4-, 7-DIAMINES, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060162099-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060162099-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, DSP, KRTCAP2 | CYP1A2 1721/4885KDM4E 279/4885MEN1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.